Study: MAP1LC3C as A Drug Target (G440738)

Target Name: MAP1LC3C

NCBI ID: G440738

MAP1LC3C

Study: MAP1LC3C as A Drug Target

MAP1LC3C, also known as Microtubule-associated proteins 1A/1B light chain 3C, is a protein that is expressed in a variety of tissues and cells throughout the body. It is a key component of microtubules, which are the protein structures that form the foundation of the cytoskeleton in eukaryotic cells. MAP1LC3C is involved in the regulation of microtubule dynamics and stability, and is thought to play a role in a variety of cellular processes, including cell division, intracellular transport, and cell signaling.

In recent years, researchers have become increasingly interested in the potential therapeutic uses of MAP1LC3C as a drug target. This is because the regulation of microtubule dynamics by MAP1LC3C is thought to be disrupted in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. By targeting MAP1LC3C with small molecules or other therapeutic agents, researchers hope to improve the delivery and activity of these molecules, potentially leading to therapeutic benefits.

One of the challenges in studying MAP1LC3C as a drug target is its complex and highly regulated structure. MAP1LC3C is a 21-kDa protein that is composed of a catalytic light chain and a variable region that includes a transmembrane domain and several potential interaction sites. The catalytic light chain consists of two alpha-helices that form the active site for the protein's catalytic activity, while the variable region includes a variety of secondary structure elements that are involved in the regulation of microtubule dynamics.

To study the regulation of MAP1LC3C, researchers have used a variety of techniques, including biochemical, cellular, and structural studies. One of the most promising approaches has been to use small molecules to stabilize or inhibit the activity of MAP1LC3C. This has led to the development of a number of potential drug candidates that target MAP1LC3C, including inhibitors of the protein's catalytic activity and modulators of its stability.

One of the most promising drug candidates is a small molecule called N-Acetyl-L-Aspartate (NAA), which is known to inhibit the activity of MAP1LC3C. NAA has been shown to stabilize MAP1LC3C in cell culture, and to inhibit its catalytic activity in a variety of cell types. NAA also appears to have a number of potential therapeutic benefits, including the potential to treat a variety of neurodegenerative diseases and to improve the delivery of other therapeutic agents.

Another promising drug candidate is a peptide called P120, which is derived from the tail of MAP1LC3C. P120 has been shown to inhibit the activity of MAP1LC3C in cell culture, and to improve the stability of the protein in a variety of cell types. P120 also appears to have a number of potential therapeutic benefits, including the potential to treat a variety of neurodegenerative diseases and to improve the delivery of other therapeutic agents.

While the development of potential drug candidates for MAP1LC3C is an promising approach to studying the protein and its potential therapeutic uses, there are also challenges that must be addressed. For example, the regulation of MAP1LC3C by intracellular signaling pathways is complex and highly regulated, making it difficult to predict the effects of small molecules or other therapeutic agents. Additionally, the structure and function of MAP1LC3C are not well understood, which can make it difficult to design and optimize small molecules or other therapeutic agents.

Despite these challenges, however, the potential therapeutic uses of MAP1LC3C are

Protein Name: Microtubule Associated Protein 1 Light Chain 3 Gamma

Functions: Ubiquitin-like modifier that plays a crucial role in antibacterial autophagy (xenophagy) through the selective binding of CALCOCO2 (PubMed:23022382). Recruits all ATG8 family members to infecting bacteria such as S.typhimurium (PubMed:23022382). May also play a role in aggrephagy, the macroautophagic degradation of ubiquitinated and aggregated proteins (PubMed:28404643)

The "MAP1LC3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP1LC3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets